Filing Details
- Accession Number:
- 0001209191-23-017161
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-08 16:05:34
- Reporting Period:
- 2023-03-06
- Accepted Time:
- 2023-03-08 16:05:34
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
818686 | Teva Pharmaceutical Industries Ltd | TEVA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1722360 | Matthew David Stark | C/O Teva Pharmaceutical Industries Ltd. 124 Dvora Hanevi'A St., Tel Aviv L3 6944020 | Exec. Vp Chief Legal Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Disposition | 2023-03-06 | 16,491 | $9.93 | 52,449 | No | 4 | S | Direct | |
Ordinary Shares | Disposition | 2023-03-07 | 49,475 | $9.43 | 2,974 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.